Quantitative phosphoproteomics revealed interplay between Syk and Lyn in the resistance to nilotinib in chronic myeloid leukemia cells
- 25 August 2011
- journal article
- Published by American Society of Hematology in Blood
- Vol. 118 (8) , 2211-2221
Abstract
In this study, we have addressed how Lyn kinase signaling mediates nilotinib-resistance by quantitative phospho-proteomics using Stable Isotope Labeling with Amino acid in Cell culture. We have found an increased tyrosine phosphorylation of 2 additional tyrosine kinases in nilotinib-resistant cells: the spleen tyrosine kinase Syk and the UFO family receptor tyrosine kinase Axl. This increased tyrosine phosphorylation involved an interaction of these tyrosine kinases with Lyn. Inhibition of Syk by the inhibitors R406 or BAY 61-3606 or by RNA interference restored the capacity of nilotinib to inhibit cell proliferation. Conversely, coexpression of Lyn and Syk were required to fully induce resistance to nilotinib in drug-sensitive cells. Surprisingly, the knockdown of Syk also strongly decreased tyrosine phosphorylation of Lyn and Axl, thus uncovering interplay between Syk and Lyn. We have shown the involvement of the adaptor protein CDCP-1 in resistance to nilotinib. Interestingly, the expression of Axl and CDCP1 were found increased both in a nilotinib-resistant cell line and in nilotinib-resistant CML patients. We conclude that an oncogenic signaling mediated by Lyn and Syk can bypass the need of Bcr-Abl in CML cells. Thus, targeting these kinases may be of therapeutic value to override imatinib or nilotinib resistance in CML.Keywords
This publication has 38 references indexed in Scilit:
- Quantitative Phosphoproteomics Reveals a Cluster of Tyrosine Kinases That Mediates Src Invasive Activity in Advanced Colon Carcinoma CellsCancer Research, 2009
- Evidence that Resistance to Nilotinib May Be Due to BCR-ABL, Pgp, or Src Kinase OverexpressionCancer Research, 2008
- Murine Retroviral but not Human Cellular Promoters Induce In Vivo Erythroid-specific Deregulation that can be Partially Prevented by InsulatorsMolecular Therapy, 2007
- Characterization of AMN107, a selective inhibitor of native and mutant Bcr-AblCancer Cell, 2005
- BMS-345541 Is a Highly Selective Inhibitor of IκB Kinase That Binds at an Allosteric Site of the Enzyme and Blocks NF-κB-dependent Transcription in MiceJournal of Biological Chemistry, 2003
- The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype [editorial; comment]Blood, 1996
- Tyrosine Kinase Activity and Transformation Potency of bcr-abl Oncogene ProductsScience, 1990
- Induction of Chronic Myelogenous Leukemia in Mice by the P210
bcr/abl
Gene of the Philadelphia ChromosomeScience, 1990
- Oncogene Activation by Chromosomal Translocation in Chronic Myelocytic LeukemiaCold Spring Harbor Symposia on Quantitative Biology, 1986
- Chromosome Abnormalities in Malignant Hematologic Diseases1982